Tag Archives: PSCK9

April, 2016

  • 1 April

    Pfizer’s PCSK9 Inhibitor Succeeds in its Second Late-Stage Study

    NEW YORK–(BUSINESS WIRE)–Pfizer Inc. announced that the Phase 3 SPIRE-AI (AutoInjector) trial of the investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i) bococizumab administered with a pre-filled pen met its co-primary endpoints: percent change from baseline in low-density lipoprotein cholesterol (LDL-C) reduction at 12 weeks compared to placebo and …